文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 工程科技 > 电子/电路 > 10.Ram et al. Am J Cardiol 2011;107 1346–1352.
侵权投诉

10.Ram et al. Am J Cardiol 2011;107 1346–1352.

ManagementofHypertensioninPatientsWithDiabetesUsinganAmlodipine-,OlmesartanMedoxomil-,andHydrochlorothiazide-BasedTitrationRegimen

C.VenkataRam,MDa,*,RichardSachson,MDb,ThomasLittlejohn,MDc,ChunlinQian,PhDd,

AliShojaee,PharmDd,KathyA.Stoakes,RN,BSNd,andJoelM.Neutel,MDe

Thesafetyandef cacyofanamlodipine/olmesartanmedoxomil(OM)-basedtitrationregimenwasassessedinpatientswithtype2diabetesmellitusandhypertension.Aftera2-to3-weekplaceborun-inperiod,207patientsreceivedamlodipine5mgandwereuptitratedtoamlodip-ine/OM5/20,5/40,and10/40mgandthenamlodipine/OM10/40mgplushydrochlorothiazide12.5and25mginastep-wisemannerat3-weekintervalsiftheseatedbloodpressure(BP)remained>120/70mmHg.Theprimaryendpointwasthechangefrombaselineinthemean24-hourambulatorysystolicBPafter12weeksoftreatment.Thebaselinemean SDseatedcuffsystolic/diastolicBPwas158.8 13.1/89.1 10.1mmHgandthemean SD24-hourambulatorysystolic/diastolicBPwas144.4 11.7/81.6 9.8mmHg.Atweek12,thechangefrombaselineinthemean SEM24-hourambulatorysystolic/diastolicBPwas 19.9 0.8/ 11.2 0.5mmHg(p<0.0001vsbaseline),and70%ofpatientshadachieveda24-hourambulatoryBPtargetof<130/80mmHg.Attheendof18weeksofactivetreatmentinpatientsuptitratedtoamlodipine/OM10/40mgplushydrochlorothiazide25mg,thechangefrombaselineinthemean SEMseatedBPwas 28.0 1.5/ 13.7 1.0mmHg(p<0.0001vsbaseline),with62%ofpatientsreachingtheguideline-recommendedseatedBPgoalof<130/80mmHg.Drug-relatedtreatment-emergentadverseeventsoccurredin19.3%ofpatients.Themostfrequenteventswereperipheraledema(6%),dizziness(3%),andhypotension(2%).Inconclusion,thisamlodipine/OM-basedtitrationregimenwaswelltoleratedandeffectivelyloweredBPthroughoutthe24-hourdosingintervalinpatientswithhypertensionandtype2diabetes.©2011ElsevierInc.Allrightsreserved.(AmJCardiol2011;107:1346–1352)

TheAZORTrialEvaluatingBloodPressureReductionsandControl(AZTEC)studyshowedthatanamlodipine/olmesartanmedoxomil(OM)-basedtitrationregimencon-UniversityofTexasSouthwesternMedicalSchool,Dallas,Texas;EndocrineAssociatesofDallas,Dallas,Texas;cPiedmontMedicalRe-searchAssociates,Winston-Salem,NorthCarolina;dDaiichiSankyo,Inc.,Parsippany,NewJersey;andeOrangeCountyResearchCenter,Tustin,California.ManuscriptreceivedSeptember28,2010;manuscriptreceivedandacceptedDecember31,2010.

ThisstudywassupportedbyDaiichiSankyo,Inc.,Parsippany,NewJersey.C.V.Ramisamemberofthespeakers’and/orconsultants’bureausforAHM,AdvancedHealthMedia(Bridgewater,NewJersey),andThePeerGroup,Inc.(Edison,NewJersey),whichconducteducationalandinteractiveprogramsforvariouspharmaceuticalandmedicaldevicescompanies.R.Sachsonisamemberofthespeakers’bureausforAbbottLaboratories(AbbottPark,Illinois),Amgen(ThousandOaks,California),AmylinPharmaceuticals(SanDiego,California),EliLilly(Indianapolis,Indiana),Genentech(SouthSanFrancisco,California),GlaxoSmithKline(ResearchTrianglePark,NorthCarolina),Novartis(Basel,Switzerland),NovoNordisk(Princeton,NewJer-sey),Solvay(Brussels,Belgium),andTakedaPharmaceuticals(Deer eld,Illinois).T.Littlejohnhasnothingtodisclose.C.Qian,A.Shojaee,andK.A.StoakesareallemployeesofDaiichiSankyo,Inc(Parsippany,NewJersey).J.M.Neutelisamemberofthespeakers’bureauforBoehringerIngelheim(Ridge eld,Connecticut),DaiichiSankyo,Inc.(Parsippany,NewJersey),Forest(NewYork,NewYork),Novartis(Basel,Switzerland),P zer(NewYork,NewYork),andSano -aventis/Bristol-MyersSquibb(Bridgewater,NewJerseyandPrinceton,NewJersey).

*Correspondingauthor:Tel:(214)358-2300,ext.6125;fax:(214)366-6027.E-mailaddress:ramv@dneph.com(C.V.Ram).

b

a

trolledbloodpressure(BP)fora24-hourperiodinpatientswithhypertension.1ThepresentstudyisaProspective,open-label,ambulatoryBPmonitoringstudytoevaluatethesafetyandEf cacyofanolmesartanmedoXomil-andam-lodipine-basedtreatmentregimeninpatientswithtype2diabetesandhypertension(APEX).Theef cacyandtoler-abilitywereevaluatedafter12weeksoftreatment.Inad-dition,theeffectofaddinghydrochlorothiazide(HCTZ)totheregimenforanadditional6weekswasassessed.Methods

ThepresentphaseIV,open-label,multicenter,single-arm,titrationstudyconsistedofa3-to14-dayscreeningperiod,a2-to3-weekplaceborun-inperiod,andan18-weekactivetreatmentphase(Figure1).Ateachclinicvisit,theseatedBPandheartrateweredeterminedintriplicatefromthepatient’snondominantarmusinganautomatedOmrondevice.ASpacelabsHealthcare90207Oscillomet-ricdevice(Issaquah,WA)wasusedtoperform24-hourambulatoryBPmonitoringatbaselineandafter12weeksofactivetreatment.Themonitoringwasstartedat8A.M. 2hoursimmediatelybeforedosing.Thesametimewindowwasmonitoredatbaselineandweek12.Thepresentstudywasconductedinaccordancewiththeinstitutionalreviewboards’committeeregulationsandtheDeclarationofHel-sinki.Theinstitutionalreviewboardoversawthestudyateachsite.Allpatientsprovidedinformedconsentbeforestudyparticipation.

doc.guandang.net

0002-9149/11/$–seefrontmatter©2011ElsevierInc.Allrightsreserved.doi:10.1016/j.amjcard.2010.12.045

第1页

你可能喜欢

热门文档

相关文档

  • 优化PCI抗栓策略

    Andres Fernandez,et al. Am J Cardiol 2011;107:6-9. ARMYDA-4 RELOAD研究 长期服用氯吡格雷的稳定性心绞痛患者,PCI术前服 用600mg的氯吡格雷未见明显获益 ...

  • 优化PCI抗栓策略-吕树铮

    Am J Cardiol 2011;107:6-9. ARMYDA-4 RELOAD研究 长期服用氯吡格雷的稳定...Steffen Massberg,et al.European Heart Journal,2010,31:1298-1300 基于循证...

  • 2013-益适纯推广故事

    Bays HE, et al. Am J Cardiol 2011;108:523-530. 仅供医学药学专业人士阅读 大剂量他汀单药治疗显著增加不良事件 药物相关不良事件 任何不良事件 任何需停用...

  • 《急性冠状动脉综合征患者强化他汀治疗专家共识》沈法荣

    Am J Cardiol. 2011;108(1):1-7 Quintavalle C, et al. Circulation. ...[suppl]:89C–94C Am J Gastroenterol 2012; 107: 811– 826; 由于缺乏NAFLD...

  • 从指南更新看BB在高血压治疗中的地位0609

    β受体阻滞剂显著降低 高血压伴冠心病患者四年死亡率 P<0.01 四年死亡率 n=534 n=691 Haim M, et al. Am J Cardiol. 1998;81:1455-1460. β受体阻滞...

  • 强效降血脂,安全新主张

    (n=8901) 1352 (15.2) 1421 (16.0) 10 (0...Newman C, et al. Am J Cardiol 2006;97:61–...3、Shepherd J, et al. Cardiology. 2007;107(4...

  • 他汀的抗动脉粥样硬化

    Am J Cardiol.2002;90:942-6; Ballantyne CM et al. Circulation.2003;107:2409-15 他汀的早期获益与降脂外作用有关 降脂 + ? 改善内皮功能 ? 抗炎 ? 抗...

  • 医学心理学-心身医学诊治进展

    / General Hospital Psychiatry 33 (2011) 8–15 心理——植物神经症状群 I....Todaro et al. Am J Cardiol. 2003;92:901. 心脏病与焦虑 ? 心脏移植改善...

  • 2013 ACCAHA胆固醇治疗指南-安全性推荐解读

    (N=3,107) 肾功能 正常 37.4% 不合并CKD (N=6,894) (MDRD方程 估算...Shepherd J et al. J Am Coll Cardiol. 2008;51:1448-1454. PLANET研究设计...

  • 丁燕生-心律失常的“上游治疗”2011.11

    心肌病 心血管病与心房颤动发生 的危险预测 ——Kannel WB, et al.Am J Cardiol. 1998 Oct 16;82(8A):2N-9N ——Sumeet S, et al. Prog Cardiovasc Dis...

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email